Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB-728-T
- Development stage
- Phase 2
- Lead developer
- Sangamo Therapeutics
- Modality
- Zinc Finger Nucleases → Other Nucleases → Programmable Nucleases → Gene Editing → Gene Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SB-728-T is an investigational gene therapy product developed to treat HIV infection. It consists of autologous CD4 T cells that have been genetically modified ex vivo using zinc finger nucleases (ZFNs) delivered via adenovirus vector or mRNA to disrupt the CCR5 gene. The targeted disruption of the CCR5 gene prevents expression of the C-C chemokine receptor type 5 (CCR5) receptor on CD4 cells—a key co-receptor required for HIV entry—rendering these cells resistant to infection by the most common strain of HIV. This approach is inspired by individuals with a natural homozygous CCR5-delta32 mutation who are highly resistant to HIV infection. The therapy aims to provide patients with a durable pool of immune cells that are less susceptible or resistant to HIV, potentially improving immune restoration and offering functional control over the virus[1][2][3][4][6].
- Other names
- CD4 CAR+ ZFN-modified T CellsAutologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIVZFN Modified CD4+T cells
02
Targets
CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on SB-728-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB-728-T.